Marco A De Velasco

List of Publications by Year
in descending order

161 papers	2,809 citations	159525 30 h-index	197736 49 g-index
162 all docs	162 docs citations	162 times ranked	5082 citing authors

#	Article	IF	Citations
1	A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors. Cancer Research, 2004, 64, 5913-5919.	0.4	334
2	FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth. Cancer Research, 2010, 70, 2053-2063.	0.4	169
3	A Novel Human AlkB Homologue, ALKBH8, Contributes to Human Bladder Cancer Progression. Cancer Research, 2009, 69, 3157-3164.	0.4	135
4	The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Oncogene, 2015, 34, 199-208.	2.6	115
5	Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen. Gastroenterology, 2000, 119, 162-171.	0.6	103
6	Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. International Journal of Cancer, 1995, 60, 515-519.	2.3	89
7	Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer. British Journal of Cancer, 2011, 105, 1210-1217.	2.9	83
8	Sensitivities to various epidermal growth factor receptorâ€tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptorâ€tyrosine kinase inhibitor?. Cancer Science, 2016, 107, 1134-1140.	1.7	78
9	Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Letters, 2015, 356, 819-827.	3.2	75
10	Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer, 2008, 112, 2352-2358.	2.0	56
11	Protective effects of zinc chelation in traumatic brain injury correlate with upregulation of neuroprotective genes in rat brain. Neuroscience Letters, 2004, 355, 221-225.	1.0	55
12	Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. International Journal of Oncology, 2014, 45, 1430-1436.	1.4	52
13	Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget, 2014, 5, 2962-2973.	0.8	51
14	Role of syndecanâ€1 (CD138) in cell survival of human urothelial carcinoma. Cancer Science, 2010, 101, 155-160.	1.7	47
15	Intestinal expression of mutant and wild-type progastrin significantly increases colon carcinogenesis in response to azoxymethane in transgenic mice. Cancer, 2004, 100, 1311-1323.	2.0	45
16	Inhibition of Î²-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Nonâ€“small-cell Lung Cancer with a T790M Mutation. Journal of Thoracic Oncology, 2015, 10, 93-101.	0.5	44
17	KIAA1199 interacts with glycogen phosphorylase kinase Î²-subunit (PHKB) to promote glycogen breakdown and cancer cell survival. Oncotarget, 2014, 5, 7040-7050.	0.8	44
18	Syndecanâ€1, a new target molecule involved in progression of androgenâ€independent prostate cancer. Cancer Science, 2009, 100, 1248-1254.	1.7	43

#	Article	IF	Citations
19	Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. International Journal of Oncology, 2015, 46, 1025-1030.	1.4	42
20	Prostate cancer immunotherapy. Current Opinion in Urology, 2018, 28, 15-24.	0.9	40
21	Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Molecular Cancer Therapeutics, 2008, 7, 1864-1870.	1.9	38
22	Allium vegetables: their role in the prevention of cancer. Biochemical Society Transactions, 1996, 24, 811-814.	1.6	37
23	Micronuclei, a biomarker for chemoprevention trials: Results of a randomized study in oral pre-malignancy. International Journal of Cancer, 1994, 59, 457-459.	2.3	36
24	Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget, 2016, 7, 49091-49098.	0.8	35
25	Gut microbiome and prostate cancer. International Journal of Urology, 2022, 29, 793-798.	0.5	35
26	Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo. Clinical Cancer Research, 2011, 17, 1373-1381.	3.2	34
27	Carvedilol protects tubular epithelial cells from ischemiaâ€“reperfusion injury by inhibiting oxidative stress. International Journal of Urology, 2010, 17, 989-995.	0.5	32
28	Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Molecular Cancer, 2014, 13, 126.	7.9	31
29	Identification of Programmed Death Ligand 1â€“derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma. Journal of Immunotherapy, 2015, 38, 285-291.	1.2	31
30	Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal. Lung Cancer, 2015, 88, 16-23.	0.9	31
31	<scp>FGFR</scp> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Science, 2016, 107, 1667-1676.	1.7	31
32	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer, 2017, 17, 281.	1.1	31
33	Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PLoS ONE, 2015, 10, e0121891.	1.1	30
34	Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer. Molecular and Clinical Oncology, 2013, 1, 845-850.	0.4	29
35	Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. SpringerPlus, 2014, 3, 417.	1.2	29
36	Deletion of functional gastrin gene markedly increases colon carcinogenesis in response to azoxymethane in mice. Gastroenterology, 2002, 123, 516-530.	0.6	27

#	Article	IF	Citations
37	Slug increases sensitivity to tubulinâ€binding agents via the downregulation of Î²III and Î²IVaâ€tubulin in lung cancer cells. Cancer Medicine, 2013, 2, 144-154.	1.3	26
38	Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. JCI Insight, 2019, 4, .	2.3	26
39	MEK inhibitors against MET-amplified non-small cell lung cancer. International Journal of Oncology, 2016, 49, 2236-2244.	1.4	24
40	Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in aPTEN-deficient mouse model of prostate cancer. Carcinogenesis, 2014, 35, 2142-2153.	1.3	23
41	Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition. Urolithiasis, 2014, 42, 195-202.	1.2	20
42	Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. Oncotarget, 2016, 7, 15959-15976.	0.8	20
43	Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin. PLoS ONE, 2014, 9, e94772.	1.1	19
44	Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients withFGF9upregulation may be resistant to anti-EGFR therapies. Molecular Carcinogenesis, 2017, 56, 106-117.	1.3	19
45	Expression of Cellular Adhesion Proteins and Abnormal Glycoproteins in Human Aberrant Crypt Foci. Applied Immunohistochemistry and Molecular Morphology, 2004, 12, 350-355.	0.6	18
46	Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors. Investigational New Drugs, 2012, 30, 1878-1886.	1.2	18
47	Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer Letters, 2017, 405, 22-28.	3.2	17
48	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapyâ€induced colitis. Molecular Oncology, 2022, 16, 1493-1507.	2.1	17
49	<scp>l</scp>-Arginine Decreases Fluid-Percussion Injury-Induced Neuronal Nitrotyrosine Immunoreactivity in Rats. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1733-1741.	2.4	16
50	MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations. Molecular Cancer Therapeutics, 2014, 13, 3098-3106.	1.9	16
51	Clinicopathological and genetic differences between lowâ€grade and highâ€grade colorectal mucinous adenocarcinomas. Cancer, 2015, 121, 4359-4368.	2.0	16
52	Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC. Molecular Cancer Therapeutics, 2016, 15, 1988-1997.	1.9	16
53	Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International Journal of Oncology, 2017, 50, 2049-2058.	1.4	15
54	HOXA10 expression profiling in prostate cancer. Prostate, 2019, 79, 554-563.	1.2	15

#	Article	IF	Citations
55	Connecting the Dots Between the Gutâ€“IGF-1â€“Prostate Axis: A Role of IGF-1 in Prostate Carcinogenesis. Frontiers in Endocrinology, 2022, 13, 852382.	1.5	15
56	Immunological evaluation of personalized peptide vaccination monotherapy in patients with castrationâ€resistant prostate cancer. Cancer Science, 2010, 101, 601-608.	1.7	14
57	Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Advances in Urology, 2012, 2012, 1-12.	0.6	14
58	EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. International Journal of Oncology, 2015, 47, 499-505.	1.4	14
59	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Nonâ€“Small Cell Lung Cancer: Double-Edged Sword of DDR2. Clinical Cancer Research, 2016, 22, 3663-3671.	3.2	14
60	Tumor vaccines in renal cell carcinoma. World Journal of Urology, 2008, 26, 147-154.	1.2	13
61	Generation of PTENâ€'knockout (â€'/â€') murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling. Oncology Reports, 2018, 40, 2455-2466.	1.2	13
62	Micronuclei in bronchial biopsy specimens from heavy smokers: Characterization of an intermediate marker of lung carcinogenesis. International Journal of Cancer, 1992, 52, 44-47.	2.3	12
63	Effects of the <scp>R</scp>ho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with <scp>HCl</scp>â€induced cystitis. International Journal of Urology, 2013, 20, 1136-1143.	0.5	12
64	Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. Journal of Translational Medicine, 2015, 13, 150.	1.8	12
65	An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer. Annals of Oncology, 2015, 26, 1800-1801.	0.6	11
66	Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis. Scientific Reports, 2020, 10, 19186.	1.6	10
67	Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. Frontiers in Oncology, 2021, 11, 763468.	1.3	10
68	Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. SpringerPlus, 2015, 4, 7.	1.2	9
69	Hypoxia-inducing factor (HIF)-1Î±-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. International Immunopharmacology, 2017, 44, 197-202.	1.7	9
70	Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer. Human Cell, 2020, 33, 730-736.	1.2	8
71	Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. International Immunopharmacology, 2014, 20, 59-65.	1.7	7
72	Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model. Cancers, 2021, 13, 3683.	1.7	7

#	Article	IF	Citations
73	Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1827-1831.	0.5	7
74	Abstract 4702: PD-L1 blockade in preclinical models ofPTEN-deficient prostate cancer. , 2017, , .		6
75	Performance of Idyllaâ„¢ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer. International Journal of Clinical Oncology, 2022, 27, 1180-1187.	1.0	5
76	A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system. Oncology Reports, 2011, 26, 327-33.	1.2	4
77	Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer. Cancers, 2021, 13, 3975.	1.7	4
78	SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions. PLoS ONE, 2017, 12, e0184154.	1.1	4
79	New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles. International Immunopharmacology, 2015, 26, 133-138.	1.7	3
80	Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients. Translational Andrology and Urology, 2021, 10, 2838-2847.	0.6	2
81	Abstract 1568: A2aR inhibition enhances the antitumor activity of CTLA4 blockade in mouse Pten-deficient prostate cancer. Cancer Research, 2021, 81, 1568-1568.	0.4	2
82	Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	2
83	Abstract 4699: Preclinical activity of the AKT inhibitor AZD5363 in PTEN-deficient mouse models of prostate cancer. Cancer Research, 2015, 75, 4699-4699.	0.4	2
84	Abstract 3629: HOXA10 expression profiles in prostate cancer. , 2012, , .		1
85	Abstract 3864: The Jak1/2 inhibitor AZD1480 suppresses tumor growth and metastasis in genetically engineered mouse models of PTEN-deficient prostate cancer. , 2016, , .		1
86	Abstract 5169: Novel target molecules for treatment of cancer of unknown primary. , 2018, , .		1
87	Abstract 3340: Prostate cancer alters gut microbiota in mice. , 2020, , .		1
88	Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period. Hepatology International, 2022, 16, 135-147.	1.9	1
89	GFP image analysis in the mouse orthotopic bladder cancer model. Oncology Reports, 2008, 20, 543-7.	1.2	1
90	GFP image analysis in the mouse orthotopic bladder cancer model. Oncology Reports, 1994, 20, 543.	1.2	0

#	Article	IF	Citations
91	882: Intravesical Instillation of Liposomal Doxorubicin Nanoparticles in Mouse Superficial Bladder Cancer. Journal of Urology, 2007, 177, 293-293.	0.2	0
92	A NOVEL p16 PEPTIDE THERAPY RADIOSENSITIZES PROSTATE CANCER. Journal of Urology, 2008, 179, 228-229.	0.2	0
93	FUNCTIONAL PEPTIDE THERAPY WITH PTEN IN PROSTATE CANCER. Journal of Urology, 2008, 179, 224-224.	0.2	0
94	1769 A PHASE I TRIAL OF VEGFR1 PEPTIDE VACCINES FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2011, 185, .	0.2	0
95	Intravesical Bacillus Calmette-Guerin Therapy for Grade 3 Non-Muscle Invasive Bladder Cancer: Results of Six or Eight Successive Instillations. Current Urology, 2011, 5, 41-45.	0.4	0
96	Construction of a 3D Culture Assay System for Anti-Cancer Drug Testing. Annals of Oncology, 2013, 24, ix77.	0.6	0
97	259 Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer. European Journal of Cancer, 2015, 51, S46.	1.3	0
98	EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. Annals of Oncology, 2015, 26, vii129.	0.6	0
99	Abstract 1780: Associations between gut microbiota and PD-L1 immunotherapy/JAK1/2 inhibition in mousePten-deficient prostate cancer. , 2021, , .		0
100	Abstract 1781: Correlates of androgen deprivation and gut microbiome in mousePten-deficient prostate cancer. , 2021, , .		0
101	Abstract 622: Gene panel-based immune profiling of human cancers. , 2021, , .		0
102	Abstract 1438: Acute immune responses to apalutamide in mousePten-deficient prostate cancer. , 2021, , .		0
103	650: The Role of PTEN in Hormone Independent Prostate Cancer Derived by Prostate Specific Deletion of PTEN. Journal of Urology, 2007, 177, 218-219.	0.2	0
104	Abstract 956: Targeting prostate cancer chemoprevention via the androgen receptor in a preclinical mouse model. , 2010, , .		0
105	Abstract 843: Increased consumption of dietary fat contributes to increased prostate cancer-specific mortality in a transgenic mouse model of prostate cancer. , 2011, , .		0
106	Abstract 3579: Sorafenib inhibits tumor development and growth in a transgenic mouse model of prostate cancer. , 2011, , .		0
107	Abstract 2167: Identification of aberrant expression of HOXA10 in prostate cancer. , 2011, , .		0
108	Abstract 1095: Short Poly A sequence in HGF promoter region is involved in overexpression of HGF in cancer cells. , 2011, , .		0

#	Article	IF	Citations
109	Abstract 433: Altered expression of lumican in prostate cancer is identified by microarray analysis. , 2011, , .		0
110	Abstract 806: Anti-tumor effects of low temperature whole body hyperthermia on human bladder cancer cellsin vivo. , 2011, , .		0
111	Abstract 539: A preclinical model to evaluate the risk of increased dietary fat consumption and prostate cancer progression. , 2012, , .		0
112	Abstract 424: Amplification ofOCT4-pseudogenePOU5F1Bis a poor prognostic factor in gastric cancer. , 2012, , .		0
113	Abstract 3876: Role of Stat3 transcriptional activation in a preclinical mouse model of prostate cancer and potential as a therapeutic target. , 2012, , .		0
114	Abstract 2755: Enhanced anti-tumor effects using a combinatorial targeted treatment strategy in a preclinical model of prostate cancer. , 2012, , .		0
115	Abstract 5178: Evaluation of lumican expression profiles in prostate cancer. , 2012, , .		0
116	Abstract 3517: Use of a novel synthetic biomaterial to induce mild whole body hyperthermia for the treatment of cancer in a preclinical model. , 2012, , .		0
117	Abstract 3688: Leptin contributes to prostate cancer progression.. , 2013, , .		0
118	Abstract 4608: Autophagy is required for prostate cancer progression.. , 2013, , .		0
119	Abstract 1201: Establishment and characterization of cell lines derived from a murine model of PTEN-deficient prostate cancer. , 2014, , .		0
120	Abstract 3912: The role of autophagy in prostate tumorigenesis and its therapeutic implications. , 2014, , .		0
121	Abstract 4729: Expression of lumican is negatively associated with the risk of biochemical recurrence in human prostate cancer. , 2014, , .		0
122	Abstract 5271: Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. , 2014, , .		0
123	Abstract 613: Combining PI3K and 5alpha-reductase inhibitors improves the treatment response in a mouse model of PTEN-deficient prostate cancer. , 2014, , .		0
124	Abstract 84: Functional evaluation of synchronous inactivation of PTEN and P53 in a murine model of prostate cancer. , 2014, , .		0
125	Abstract 611: Co-targeting the PI3K and androgen receptor signal pathways in castration resistant prostate cancer. , 2014, , .		0
126	Abstract 1845: Chloroquine demonstrates limited effectiveness in an autochthonous preclinical model of prostate cancer. , 2015, , .		0

#	Article	IF	Citations
127	Abstract 4958: Melanoma transition is frequently accompanied by a loss of cytoglobin, a putative tumor suppressor, in melanocytes. , 2015, , .		0
128	Abstract 1857: Effects of long-term chloroquine chemotherapy in a preclinical model of PTEN-deficient prostate cancer. , 2015, , .		0
129	Abstract 1856: Preclinical effects of dual AKT/MAPK inhibition in PTEN-deficient prostate cancer. , 2015, , .		0
130	Abstract 5456: FGF9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer. , 2015, , .		0
131	Abstract 3402: Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. , 2015, , .		0
132	Abstract 4212: Inhibition of mouse PTEN-deficient prostate cancer with next generation antisense oligonucleotide targeting the androgen receptor. , 2015, , .		0
133	Abstract 1850: Evaluation of Pim-1 kinase inhibition in a preclinical model of mouse prostate cancer. , 2015, , .		0
134	An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small cell lung cancer. Annals of Oncology, 2015, 26, vii73.	0.6	0
135	Abstract 3538: Effects of oral chloroquine administration on a preclinical mouse model of PTEN/p53-deficient prostate cancer. , 2016, , .		0
136	Abstract 4315: Effects of increased dietary fat consumption on prostate cancer progression in genetically engineered mice. , 2016, , .		0
137	Abstract 954: Analysis of noncoding RNA expression in a mouse model of PTEN-deficient prostate cancer. , 2016, , .		0
138	Abstract 2014: Alternative splicing is a frequent event in mouse PTEN-deficient prostate cancer. , 2016, , .		0
139	Abstract 1096: Co-targeting of AKT and Pim kinases in mousePTEN-deficient prostate cancer. , 2017, , .		0
140	Abstract 1582: Therapeutic potential of combination therapy using a next generation antisense oligonucleotide targeting the androgen receptor and AKT inhibition with AZD5363 in genetically engineered mouse models of prostate cancer. , 2017, , .		0
141	Abstract 751: Characterization of STAT3 activation in human prostate cancer. , 2017, , .		0
142	Abstract 3684: Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models. , 2017, , .		0
143	Abstract 3737: Apalutamide (ARN-509) demonstrates therapeutic efficacy in genetically engineered mouse models ofPten-deficient prostate cancer. , 2018, , .		0
144	Abstract 4825: Targeting PIM and AKT kinases impairs tumor growth and improves overall survival in a murine model of advanced castration-resistant prostate cancer. , 2018, , .		0

#	Article	IF	Citations
145	Abstract 4439: Genetic alterations in specific RNA processing genes is associated with poor patient outcome in prostate cancer. , 2018, , .		0
146	Abstract 2868: Preclinical evaluation of the multi tyrosine kinase inhibitor TAS-115 in genetically engineered mouse models of prostate cancer. , 2018, , .		0
147	Abstract 947: Influence of abiraterone therapy on anti-tumor immunity in genetically engineered mouse prostate cancer models. , 2018, , .		0
148	Abstract 1715: Treatment-dependent effects of androgen receptor signaling suppression on immune modulation in mousePten-deficient prostate cancer. , 2018, , .		0
149	Abstract 3951: Apalutamide reworks the immune composition of prostate tumors. , 2019, , .		0
150	Abstract 4996: A real-time PCR-based approach to quantitatively assess tumor immune profiles and immune responses. , 2019, , .		0
151	Abstract 5023: Immunomodulation of the multi-tyrosine kinase inhibitor TAS-115 in a mouse model of prostate cancer. , 2019, , .		0
152	Abstract 1613: Dietary isoflavone decreases prostate cancer progression and improves survival in conditionalPten/Trp53-deficient mice. , 2019, , .		0
153	Abstract 4468: Cross-species analysis and immunophenotyping using of a focused panel of immune-responsive genes. , 2020, , .		0
154	Abstract 3341: Systemic targeted JAK1/2 therapy for mousePten-deficient prostate cancer model influences the diversity and composition of the gut microbiome. , 2020, , .		0
155	Abstract 5610: The multi tyrosine kinase inhibitor TAS-115 promotes innate and adaptive immune responses of androgen deprivation therapy in mouse prostate cancer. , 2020, , .		0
156	Abstract 3416: Androgen deprivation following JAK1/2 and PD-L1 inhibition improves antitumor efficacy in mouse models ofPten-deficient prostate cancer. , 2020, , .		0
157	Abstract 1071: Targeting A2aR in mousePten-deficient prostate cancer. , 2020, , .		0
158	Abstract 1613: Dietary isoflavone decreases prostate cancer progression and improves survival in conditionalPten/Trp53-deficient mice. , 2019, , .		0
159	Abstract 3951: Apalutamide reworks the immune composition of prostate tumors. , 2019, , .		0
160	Abstract 4996: A real-time PCR-based approach to quantitatively assess tumor immune profiles and immune responses. , 2019, , .		0
161	Abstract 5023: Immunomodulation of the multi-tyrosine kinase inhibitor TAS-115 in a mouse model of prostate cancer. , 2019, , .		0